Ovid Therapeutics (OVID) Competitors $0.37 +0.04 (+10.52%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.39 +0.01 (+3.74%) As of 07/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. XBIT, ZNTL, SAVA, OKYO, JSPR, FBRX, CLLS, CLYM, CABA, and MCRBShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include XBiotech (XBIT), Zentalis Pharmaceuticals (ZNTL), Cassava Sciences (SAVA), OKYO Pharma (OKYO), Jasper Therapeutics (JSPR), Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Its Competitors XBiotech Zentalis Pharmaceuticals Cassava Sciences OKYO Pharma Jasper Therapeutics Forte Biosciences Cellectis Climb Bio Cabaletta Bio Seres Therapeutics XBiotech (NASDAQ:XBIT) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Does the media refer more to XBIT or OVID? In the previous week, XBiotech and XBiotech both had 1 articles in the media. XBiotech's average media sentiment score of 0.59 beat Ovid Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ovid Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is XBIT or OVID more profitable? XBiotech has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. XBiotech's return on equity of -21.14% beat Ovid Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets XBiotechN/A -21.14% -19.55% Ovid Therapeutics -4,562.23%-34.17%-25.34% Do analysts rate XBIT or OVID? Ovid Therapeutics has a consensus target price of $3.13, indicating a potential upside of 735.56%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ovid Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do insiders and institutionals believe in XBIT or OVID? 55.7% of XBiotech shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 33.1% of XBiotech shares are owned by insiders. Comparatively, 13.1% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, XBIT or OVID? Ovid Therapeutics has lower revenue, but higher earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXBiotech$4.01M23.19-$38.53M-$1.29-2.36Ovid Therapeutics$570K46.66-$26.43M-$0.35-1.07 Which has more volatility and risk, XBIT or OVID? XBiotech has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. SummaryOvid Therapeutics beats XBiotech on 9 of the 16 factors compared between the two stocks. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.06M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-1.0720.4427.2620.04Price / Sales46.66190.07381.2593.27Price / CashN/A41.7026.2128.59Price / Book0.397.397.945.55Net Income-$26.43M-$55.04M$3.17B$248.49M7 Day Performance18.35%2.51%1.80%4.87%1 Month Performance17.39%-0.21%1.28%6.63%1 Year Performance-55.25%3.41%33.57%20.38% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.2033 of 5 stars$0.37+10.5%$3.13+735.6%-49.8%$24.06M$570K-1.0760Gap UpHigh Trading VolumeXBITXBiotech0.4619 of 5 stars$2.97+6.1%N/A-46.5%$85.37M$4.01M-2.30100Positive NewsGap UpZNTLZentalis Pharmaceuticals1.5518 of 5 stars$1.16-1.7%$8.37+621.3%-67.1%$84.90M$67.43M-0.37160SAVACassava Sciences3.8856 of 5 stars$1.81+3.4%$54.50+2,911.0%-81.1%$84.54MN/A-1.2130OKYOOKYO Pharma1.8292 of 5 stars$2.57+4.9%$7.00+172.4%+135.0%$82.90MN/A0.007Positive NewsJSPRJasper Therapeutics3.3941 of 5 stars$5.55+1.1%$59.25+967.6%-85.6%$82.47MN/A-1.0620News CoverageAnalyst ForecastGap DownFBRXForte Biosciences2.5394 of 5 stars$12.93+5.6%$61.00+371.8%+55,480.0%$80.65MN/A-0.795CLLSCellectis3.0362 of 5 stars$1.53+5.2%$4.00+162.3%-21.6%$80.60M$49.22M-1.77290CLYMClimb Bio2.6152 of 5 stars$1.24+5.1%$9.00+625.8%N/A$79.74MN/A0.009Positive NewsCABACabaletta Bio1.5251 of 5 stars$1.52-3.2%$14.43+849.2%-78.9%$79.67MN/A-0.6050Positive NewsGap UpMCRBSeres Therapeutics3.5245 of 5 stars$11.11+22.1%$73.67+563.1%-33.2%$79.46M$126.32M-2.42330Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies XBIT Alternatives ZNTL Alternatives SAVA Alternatives OKYO Alternatives JSPR Alternatives FBRX Alternatives CLLS Alternatives CLYM Alternatives CABA Alternatives MCRB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.